Table 3.

Clinical Characteristics of CRKP and CSKP Strains

Variable	CRKP (n=66)	CSKP (n=66)	P-value
Demographic, n (%) or IQR
Age (years)	44.5 (0,60)	46.5 (0.61)	0.754
Sex (male)	47 (71.2%)	46 (69.7%)	0.894
Length of hospital stays	15 (7, 27)	25 (10, 38)	0.1
Admission to ICU	14 (21.1%)	7 (10.6%)	0.096
Co-morbidity, n (%)
Malignant disease	7 (10.6%)	15 (22.7%)	0.062
Diabetes mellitus	11 (16.7%)	12 (18.2%)	0.819
Hypertension	16 (24.2%)	16 (24.2%)	1
Heart disease	9 (13.6%)	11 (16.7%)	0.627
Hepatobiliary disease	12 (18.2%)	15 (22.7%)	0.517
Respiratory disease	45 (68.2%)	33 (50%)	0.034
Renal disease	7 (10.6%)	16 (24.2%)	0.039
Urinary tract infection	10 (15.2%)	9 (13.6%)	0.804
Craniocerebral disease	15 (22.7%)	9 (13.6%)	0.176
Hematological disease	32 (48.5%)	19 (28.8%)	0.02
Gastrointestinal disease	8 (12.1%)	5 (7.6%)	0.381
Invasive procedures and devices
Tracheal cannula	24 (36.4%)	7 (10.6%)	<0.001
Central venous catheter	5 (7.6%)	12 (18.2%)	0.069
Foreign material in the body	14 (21.2%)	7 (10.6%)	0.096
Surgical operations after admission	9 (13.6%)	16 (24.2%)	0.12
Colostomy	3 (4.5%)	1 (1.5%)	0.612
Gastrostomy	2 (3%)	0	0.476
Antibiotic treatment, n (%)
Penicillins	2 (3%)	5 (7.6%)	0.437
First, second-generation cephalosporins	7 (10.6%)	15 (22.7%)	0.21
Third, fourth-generation cephalosporins	17 (25.8%)	19 (28.8%)	0.696
Aminoglycosides	4 (6.1%)	1 (1.5%)	0.362
Quinolones	20 (30.3%)	21 (31.8%)	0.851
Metronidazole	0	1 (1.5%)	1
Carbapenems	30 (45.5%)	32 (48.5%)	0.727
β-lactams and β-lactamase inhibitor combination	40 (60.6%)	25 (37.9%)	0.009
Clinical outcomes, n (%)
Patient outcome: mortality	5 (7.6%)	0	0.068

Note: Bold indicates P < 0.05.

Abbreviations: IQR, interquartile range; CR, carbapenem-resistant; CS, carbapenem-susceptible; ICU, intensive care unit.